The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis

Abstract

Here, we demonstrate that an LXR inverse agonist, SR9238, is effective in reduction of hepatic steatosis, inflammation and fibrosis in an animal model of NASH. These results have important implications for the development of therapeutics for treatment NASH in humans.